Bionano Genomics Inc. Company Profile
NASDAQ: BNGOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
Market open · Delayed 15 min · as of Oct 9, 11:24 AM ET
Bionano Genomics at a glance
Bionano Genomics Inc. (NASDAQ: BNGO) is a Biotechnology: Laboratory Analytical Instruments company in the Industrials sector headquartered in San Diego, CA. Bionano Genomics is led by Dr. Albert A. Luderer Ph.D. and employs about 95 people. The company's shares have traded publicly since 2018.
At a market capitalization of $17.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001411690, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Bionano Genomics do?
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Bionano Genomics Inc.
- Ticker
- NASDAQ: BNGO
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Albert A. Luderer Ph.D.
- Employees
- 95
- Headquarters
- 9540 Towne Centre Drive, San Diego, CA, United States
- Phone
- 858 888 7600
- Website
- bionano.com
- IPO year
- 2018
- Market cap
- $17.19M
- SEC CIK
- 0001411690
- Latest annual report
- 10-K · Mar 23, 2026
Companies similar to Bionano Genomics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ASTCAstrotech Corporation (DE) | 6.92 | +1.17% | $14.54M | vs BNGO |
| HBIOHarvard Bioscience Inc. | 8.16 | +0.32% | $37.13M | vs BNGO |
| PRPOPrecipio Inc. | 23.27 | +0.33% | $41.65M | vs BNGO |
| RPIDRapid Micro Biosystems Inc. Class A | 0.8917 | +3.45% | $44.73M | vs BNGO |
| CIRCCircle8 Group Inc. | 0.4779 | +7.17% | $56.15M | vs BNGO |
| SEERSeer Inc. Class A | 2.23 | +2.54% | $123.20M | vs BNGO |
| QTRXQuanterix Corporation | 3.29 | +2.49% | $155.59M | vs BNGO |
| NAUTNautilus Biotechnology Inc. | 1.99 | +9.34% | $253.24M | vs BNGO |